152658-17-8 Usage
Description
Nalfurafine is a non-narcotic opioid drug that was first launched in Japan in March 2009. It is a potent agonist for the κ-opioid receptor and is used to treat intractable itch caused by hemodialysis in patients with chronic renal failure. Nalfurafine hydrochloride exhibits an improved safety profile compared to its predecessors and has shown significant antipruritic activity against both histamine-sensitive and histamine-resistant itch.
Uses
Used in Pharmaceutical Industry:
Nalfurafine is used as a therapeutic agent for the treatment of uremic pruritus in hemodialysis patients. It provides relief from chronic itching, which is a common symptom in 25-90% of uremic patients, particularly those with chronic renal failure requiring hemodialysis.
Nalfurafine is used as a non-narcotic opioid drug for intractable itch caused by hemodialysis, as it exhibits significant opioid κ-agonist activity without inducing aversion or preference in rats on the Conditioned Place Preference (CPP) test.
Additionally, Nalfurafine is used as a structurally related compound to naltrexone (Revia), an opioid receptor antagonist marketed for treating alcohol dependence. Nalfurafine is synthesized in two steps starting from naltrexone, via reductive amination with methylamine under catalytic hydrogenation conditions, and subsequent acylation with 3(E)-(3-furyl)acryloyl chloride.
Brand Name:
Nalfurafine hydrochloride is marketed under the brand name Remitch.
Originator
Toray industries (Japan)
Check Digit Verification of cas no
The CAS Registry Mumber 152658-17-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,5,2,6,5 and 8 respectively; the second part has 2 digits, 1 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 152658-17:
(8*1)+(7*5)+(6*2)+(5*6)+(4*5)+(3*8)+(2*1)+(1*7)=138
138 % 10 = 8
So 152658-17-8 is a valid CAS Registry Number.
152658-17-8Relevant articles and documents
Crystals of morphinan derivative, manufacturing method thereof, and pharmaceutical composition using the same
-
, (2014/09/03)
The present invention relates to a X-form crystal of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[N-methyl-trans-3-(3-furyl)acrylamido]morphinan hydrochloride and the manufacturing method thereof, wherein the X-form crystal of the compound has char
CRYSTALS OF MORPHINAN DERIVATIVE AND PROCESS FOR PRODUCING THE SAME
-
Page/Page column 5; 6, (2008/06/13)
The present invention is directed to provide 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[N-methyl-trans-3-(3-furyl)acrylamido]morphinan hydrochloride consistent in quality after production and having high purity. A crystal of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[N-methyl-trans-3-(3-furyl)acrylamido]morphinan hydrochloride including a A-form, B-form or C-form crystal thereof, and a process for producing the same are provided.
